BRCA1 germline pathogenic in HER2-negative metastatic breast (HR+ or TNBC): olaparib (Oly...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-EARLY-2024 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA1 germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy, talazoparib monotherapy, olaparib adjuvant 1y (high-risk early) |
| Evidence summary | BRCA1 germline pathogenic in HER2-negative metastatic breast (HR+ or TNBC): olaparib (OlympiAD, Robson 2017) and talazoparib (EMBRACA, Litton 2018) improve PFS vs physician-choice chemotherapy. In early-stage high-risk HER2-negative: 1y adjuvant olaparib improves iDFS and OS (OlympiA, Tutt 2021). ESCAT IA / OncoKB Level 1. |
Notes
Germline finding triggers cascade testing. Adjuvant olaparib eligibility: TNBC pT≥2 or pN+, or HR+ with CPS+EG ≥3 after neoadjuvant chemo. Platinum-based chemo also active in TNBC (TNT trial).
Used By
No reverse references found in the YAML corpus.